CHOP regimen

Known as: CTX/DOX/PRED/VCR, ACOP, CHOP 
An abbreviation for a chemotherapy combination that is used to treat non-Hodgkin lymphoma and is being studied in the treatment of other types of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1973-2018
0204019732018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE We have previously shown the prognostic significance of BCL2 expression in the activated B-cell-like diffuse large B-cell… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
1Hospices Civils de Lyon and Université Lyon-1, Lyon, France; 2Hôpital Saint-Louis, Paris, France; 3Université Catholique de… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma… (More)
Is this relevant?
2006
2006
PURPOSE The chemokine receptor CXCR4 was identified as an independent predictor of poor prognosis in primary melanoma. The aim of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
BACKGROUND To determine the incidence of early cardiotoxicity induced by the CHOP regimen in patients with aggressive non-Hodgkin… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine… (More)
  • figure 1
  • figure 2
  • table 4
Is this relevant?
2002
2002
Mantle cell lymphoma (MCL) is a distinct clinico-pathological entity with a poor prognosis. We have conducted a prospective study… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To determine the safety and efficacy of the combination of the chimeric anti-CD20 antibody Rituxan (rituximab, IDEC-C2B8… (More)
Is this relevant?
1995
1995
PURPOSE To purpose of this study was to develop a more effective approach to the treatment of patients with poor-prognosis… (More)
Is this relevant?